Home The Word Brain	My Amedeo FAQ Privacy About
	Hanzi Hunter — ultra-fast Hanzi study All 1,152 characters from the aioLingua manual Abstract • About • The 20 audio files ← aioLingua Chinese Online ← Chinese aioLingua PDF

Bladder Cancer, October 2025 Free Subscription Abstracts Retrieve all available abstracts of the following 229 articles: HTML format

Single Articles

1. LI X, Wang J, Wang K, Tan S, et al
   Analysis of risk factors for postoperative bladder cancer in patients with upper tract urothelial carcinoma and construction of nomogram prediction model.
   BMC Urol. 2025;25:247.
   PubMed    
   Abstract available
   
   

2. SCHAFER JM, Song NJ, Xiao T, Gauntner TD, et al
   T cell subsets of urine-derived lymphocytes (UDLs) serve as an indicator of TILs and reflect immunological sex differences in bladder cancer.
   J Immunother Cancer. 2025;13:e012050.
   PubMed    
   Abstract available
   
   

3. LIN L, Kong L, Dong X, Ma S, et al
   Sevoflurane suppresses growth and metastasis of bladder cancer cells via inducing ferroptosis and antitumor microenvironment through Akt/mTOR/SREBP1 signaling.
   Chem Biol Interact. 2025 Oct 1:111766. doi: 10.1016/j.cbi.2025.111766.
   PubMed    
   Abstract available
   
   

4. CHEN W, Song L, Luo J, Tang J, et al
   Uranalysis-tailored fluorogenic strategy for monitoring bladder cancer biomarker hyaluronidase-1 by harnessing hydrogen-bonding-induced emission.
   Biosens Bioelectron. 2025;291:118060.
   PubMed    
   Abstract available
   
   

5. SUNGUR U, Kerim Ozfiliz N, Eksi M, Kargi T, et al
   Assessing the use of modified 5-item frailty index as a prognostic marker of long-term survival and perioperative outcomes after radical cystectomy for bladder cancer.
   Ir J Med Sci. 2025 Oct 3. doi: 10.1007/s11845-025-04108.
   PubMed    
   Abstract available
   
   

6. CHEN X, Jiang K, Chen K, An Y, et al
   HOXB7 drives bladder cancer progression via H-Ras/ERK signaling: a potential therapeutic target and prognostic biomarker.
   Front Oncol. 2025;15:1645803.
   PubMed    
   Abstract available
   
   

7. MIYAKE M, Tokumaru J, Oi H, Kitagawa H, et al
   Real-world use of maintenance bacillus Calmette-Guerin therapy in patients with non-muscle-invasive bladder cancer in Japan: ASUKA study.
   BJUI Compass. 2025;6:e70091.
   PubMed    
   Abstract available
   
   

8. ZHU Z, Zhu Y, Ying W, Wu H, et al
   Comparison of the anti-reflux ileum valve-pouch orthotopic neobladder and the Studer technique after radical cystecomy: surgical and renal functional outcomes.
   World J Surg Oncol. 2025;23:359.
   PubMed    
   Abstract available
   
   

9. KANG C, Lee J, Baek MG, Kim NE, et al
   Urinary microbiome in non-muscle invasive bladder cancer: impact of sample types and sex differences.
   BMC Microbiol. 2025;25:623.
   PubMed    
   Abstract available
   
   

10. AZHAR Z, Sadia Z
    Inlexzo (gemcitabine intravesical system): promising data but key questions remain.
    World J Urol. 2025;43:586.
    PubMed    
    Abstract available
    
    

11. BAGHERZADEH S, Roohollahi F, Kopparapu S, Carballo Cuello CM, et al
    Posterior-only total en bloc spondylectomy of L4 for solitary bladder cancer metastasis - An illustrative case.
    Surg Neurol Int. 2025;16:360.
    PubMed    
    Abstract available
    
    

12. CAYUELA L, Achaval V, Cabrera Fernandez S, Ortega Calvo M, et al
    Sex-specific bladder cancer incidence trends and generational effects in Spain.
    Actas Urol Esp (Engl Ed). 2025 Sep 29:501863. doi: 10.1016/j.acuroe.2025.501863.
    PubMed    
    Abstract available
    
    

13. PUBLISHER T
    Correction. Current status of management and outcomes of muscle-invasive bladder cancer in Yemen: a retrospective observational study.
    Arch Ital Urol Androl. 2025;97:14449.
    PubMed    
    Abstract available
    
    

14. NIZAM A, Nguyen CB, Li J, Zabor EC, et al
    Treatment-Related Adverse Events and Associated Outcomes in Patients With Advanced Urothelial Carcinoma Treated With Enfortumab Vedotin: Analysis of the UNITE Study.
    Cancer Med. 2025;14:e71284.
    PubMed    
    Abstract available
    
    

15. HOSSEINI AS, Jalali SM, Shateri Z, Shoja M, et al
    The association between digestion-resistant and bioactive peptide content of dairy products and bladder cancer: a case-control study.
    J Health Popul Nutr. 2025;44:336.
    PubMed    
    Abstract available
    
    

16. TSUKADA H, Hayakawa N, Sasaki M, Matsubara K, et al
    [Vaginal and Vulval Secondary Extramammary Paget's Disease Associated with Urothelial Carcinoma in Situ : A Case Report].
    Hinyokika Kiyo. 2025;71:301-305.
    PubMed    
    Abstract available
    
    

17. CATAL MN, Akarken I, Dere Y, Deliktas H, et al
    Prognostic difference of molecular subtypes in non-muscle invasive bladder cancer.
    Medicine (Baltimore). 2025;104:e44808.
    PubMed    
    Abstract available
    
    

18. HU A, Hu C, Lin Y, Zhu X, et al
    Causal relationship between immune cells and bladder cancer: A bidirectional Mendelian randomization study.
    Medicine (Baltimore). 2025;104:e44268.
    PubMed    
    Abstract available
    
    

19. LI H, Liang Y, Tang J, Luo H, et al
    YBX1 Enhances the Stability of TM4SF1 in an m5C-Dependent Manner to Promote Bladder Cancer Proliferation and Glycolysis.
    Comb Chem High Throughput Screen. 2025.
    PubMed    
    Abstract available
    
    

20. HE J, Dong C, Song X, Bao X, et al
    MFSD12, transcriptionally regulated by PLAGL2, promotes bladder cancer progression.
    Commun Biol. 2025;8:1402.
    PubMed    
    Abstract available
    
    

21. SILVA IM, Vacario BGL, Maraslis FT, Koike A, et al
    GLRX2 polymorphism and oxidative stress levels impact urothelial bladder cancer outcomes.
    Sci Rep. 2025;15:34041.
    PubMed    
    Abstract available
    
    

22. AMPARO TR, da Anunciacao KF, Almeida TC, de Oliveira AB, et al
    Lapachol interferes with the cell cycle and inhibits proliferation and migration of bladder tumor cells with effects on ncRNA expression.
    Sci Rep. 2025;15:33829.
    PubMed    
    Abstract available
    
    

23. ELSALEM L, Aleikish AA, Al-Azzam N, Alfaqih MA, et al
    Serum xanthine oxidoreductase and oxidative stress are associated with bladder cancer: a case-control study from Jordan.
    J Appl Biomed. 2025;23:107-116.
    PubMed    
    Abstract available
    
    

24. WANG Y, Zhou T, Hu C, Chen H, et al
    Prognostic analysis and immunotherapy prediction based on key receptor-ligand pairs of bladder cancer.
    Discov Oncol. 2025;16:1784.
    PubMed    
    Abstract available
    
    

25. MA X, Quan C
    Identification of KIF14 as a ferroptosis biomarker for predicting the prognosis and immunotherapy efficacy of bladder cancer.
    Discov Oncol. 2025;16:1786.
    PubMed    
    Abstract available
    
    

26. ESCOBAR D, Zahir M, Doshi C, Daneshmand S, et al
    Management of clinical stage T3/T4 bladder cancer: a review.
    World J Urol. 2025;43:583.
    PubMed    
    Abstract available
    
    

27. CUPRYCH-BELTER M, Lupicka-Slowik A, Anisiewicz A, Michaelis M, et al
    Distinct adaptive strategies to cisplatin, vinblastine and gemcitabine in a panel of chemoresistant bladder cancer cell lines.
    Cancer Drug Resist. 2025;8:49.
    PubMed    
    Abstract available
    
    

28. ZHOU Z, Chen Y, Wang Z, Yang S, et al
    Characterization of cancer-related fibroblasts in bladder cancer and construction of CAFs-based bladder cancer classification: insights from single-cell and multi-omics analysis.
    Front Immunol. 2025;16:1580986.
    PubMed    
    Abstract available
    
    

29. WANG L, Chang Z, Chen SY, Yang JW, et al
    Multi-omics dissection of fatty acid metabolism heterogeneity identifies PRDX1 as a prognostic marker in bladder cancer.
    Front Immunol. 2025;16:1669822.
    PubMed    
    Abstract available
    
    

30. HURLE R, Capalbo A, Lughezzani G, Buffi NM, et al
    Germline homologous recombination repair (gHRR) variants in bladder cancer: Preliminary evidence and clinical implications.
    BJUI Compass. 2025;6:e70077.
    PubMed    
    Abstract available
    
    

31. GORSKI J, Gajewski W, Ziembicki H, Pierudzka W, et al
    Nanoparticles as Drug Delivery Systems in Intravesical Therapy for Non-muscle Invasive Bladder Cancer: A Narrative Review.
    Cureus. 2025;17:e91103.
    PubMed    
    Abstract available
    
    

32. HERRANZ R, Oto J, Plana E, Perez-Ardavin J, et al
    Analysis of the Fragmentation and Integrity of Urine Cell-Free DNA as Diagnostic and Staging Biomarker for Bladder Cancer.
    J Mol Diagn. 2025 Sep 26:S1525-1578(25)00222.
    PubMed    
    Abstract available
    
    

33. OKE I, Lenert A, Swick BL, Lenert P, et al
    Eosinophilic Fasciitis in a 78-Year-Old Man Following Pembrolizumab Treatment for Bladder Cancer.
    Am J Case Rep. 2025;26:e948323.
    PubMed    
    Abstract available
    
    

34. EID S, Al-Yousef AS, Kim KW, Yoon S, et al
    State-of-the-Art Imaging in Antibody-Drug Conjugate Treatment for Advanced Bladder Cancer.
    Korean J Radiol. 2025;26:959-972.
    PubMed    
    Abstract available
    
    

35. KABUNDA J, Ndlovu H, Singh K, Sibiya S, et al
    Nectin-4, Bladder Cancer, and Nuclear Medicine: A Theranostic Frontier.
    Semin Nucl Med. 2025 Sep 26:S0001-2998(25)00118.
    PubMed    
    Abstract available
    
    

36. QAISAR R, Hussain S, Ahmad F, Karim A, et al
    Plasma CAF22 and NfL reflect neuromuscular decline during cisplatin-based chemotherapy and radical cystectomy in muscle-invasive bladder cancer.
    Int J Clin Oncol. 2025 Sep 27. doi: 10.1007/s10147-025-02890.
    PubMed    
    Abstract available
    
    

37. AKYUZ M, Kayar R, Ozsoy E, Artuk I, et al
    Impact of the CALLY Index in Predicting Overall Survival and Disease-Free Survival in Patients Undergoing Radical Cystectomy for Muscle-Invasive Bladder Cancer.
    Niger J Clin Pract. 2025;28:1090-1096.
    PubMed    
    Abstract available
    
    

38. SU M, Chen W, Luo J, Li X, et al
    E2F1-induced transcriptional activation of MAL2 inhibits sunitinib sensitivity and promotes the malignant progression of bladder cancer.
    J Chemother. 2025 Sep 26:1-12. doi: 10.1080/1120009X.2025.2561275.
    PubMed    
    Abstract available
    
    

39. REMMELINK MJ, Bloemen PR, van der Voorn P, Attendu X, et al
    Ex Vivo Optical Coherence Tomography Analysis of Resected Human Bladder with a Forward-Looking Microelectromechanical Systems Mirror-Based Catheter.
    Sensors (Basel). 2025;25:5794.
    PubMed    
    Abstract available
    
    

40. PEREIRA M, Vale N
    Exploring Potential for Repurposing Antiretroviral Drugs Etravirine and Efavirenz in Prostate and Bladder Cancer.
    Pharmaceuticals (Basel). 2025;18:1404.
    PubMed    
    Abstract available
    
    

41. SAKAI AH, Pereira ER, Santos AGPD, Quadreli DH, et al
    miR-25-3p Modulates Tumor Aggressiveness and Ferroptosis Escape in T24 Bladder Cancer Cells In Vitro.
    Pharmaceuticals (Basel). 2025;18:1382.
    PubMed    
    Abstract available
    
    

42. CUSUMANO C, Squillante F, Roma M, Miano R, et al
    Bladder Cancer: Uncovering the Predictive Role of NOTCH as an Emerging Candidate Biomarker for Therapeutic Strategies.
    Cancers (Basel). 2025;17:3078.
    PubMed    
    Abstract available
    
    

43. JURIC I, Fink EE, Qiu H, Desprez PE, et al
    Single-cell RNA-sequencing of BCG naive and recurrent non-muscle invasive bladder cancer reveals a CD6/ALCAM-mediated immune-suppressive pathway.
    NPJ Precis Oncol. 2025;9:318.
    PubMed    
    Abstract available
    
    

44. HUANG X, Meng Y, Song J, Zhu Y, et al
    Identification of biomarkers associated with mitophagy in bladder cancer.
    Sci Rep. 2025;15:33272.
    PubMed    
    Abstract available
    
    

45. OBAID K, Akpinar C, Karaburun MC, Ibis MA, et al
    A randomized prospective trial comparing Bacillus Calmette-Guerin (BCG) RIVM and Russian strains in non-muscle invasive bladder cancer: Efficacy and side effects.
    Urol Oncol. 2025 Sep 25:S1078-1439(25)00349.
    PubMed    
    Abstract available
    
    

46. TITUS RS, Mundra V, Velasquez EL, Xu J, et al
    The association between prior pelvic radiotherapy for cancer and surgical outcomes in patients undergoing radical cystectomy for bladder cancer: An analysis of national surgical quality improvement program targeted cystectomy database.
    Urol Oncol. 2025 Sep 25:S1078-1439(25)00342.
    PubMed    
    Abstract available
    
    

47. LAI S, Wu P, Liu J, Song Y, et al
    ASO Author Reflections: Navigating the Dual Threat-Bladder Cancer's Impact on Upper Tract Urothelial Carcinoma Outcomes.
    Ann Surg Oncol. 2025 Sep 26. doi: 10.1245/s10434-025-18004.
    PubMed    
    
    
    

48. MENG L, Khorasanchi A, Jain R
    Advancing Bladder Cancer Management: The Role of Neoadjuvant and Adjuvant Therapies and Biomarkers in Muscle Invasive Bladder Cancer.
    Curr Treat Options Oncol. 2025 Sep 26. doi: 10.1007/s11864-025-01355.
    PubMed    
    Abstract available
    
    

49. LIU J, Zhang Z, Huang B, Fang Y, et al
    A GRK5 centered prognostic framework for bladder cancer based on palmitoylation and epigenetic regulation.
    Discov Oncol. 2025;16:1735.
    PubMed    
    Abstract available
    
    

50. KRAEVSKA E, Popovska S
    Immunohistochemistry-Based Molecular Profiling of Muscle-Invasive Bladder Cancer: Analysis of 100 Consecutive Cases with Morphological Correlation.
    Med Sci (Basel). 2025;13:202.
    PubMed    
    Abstract available
    
    

51. WANG L, Wang Y, Wang Y, Wang Z, et al
    Prognostic value and molecular mechanism of photodynamic therapy and apoptosis related gene FGFR1 in bladder cancer.
    Front Oncol. 2025;15:1578695.
    PubMed    
    Abstract available
    
    

52. TANG Q, Li Y, Liu K, Huang G, et al
    Development and validation of a risk prediction model for distant metastasis in muscle-invasive bladder cancer: a retrospective study integrating SEER data with external validation cohort and biomarker analysis.
    Front Oncol. 2025;15:1607173.
    PubMed    
    Abstract available
    
    

53. CARVALHO FL, Lee J, Kalavros N, Zhou Y, et al
    Tumor-myeloid crosstalk drives therapy resistance in localized bladder cancer.
    bioRxiv [Preprint]. 2025 Sep 15:2025.09.08.674862.
    PubMed    
    Abstract available
    
    

54. SILVA LWPE, Almeida TC, Teixeira MSDS, Cerrutti CMV, et al
    Antiproliferative Effects of the Triterpene Ursolic Acid Natural Product in Bladder and Ovarian Tumor Cell Lines.
    Drug Dev Res. 2025;86:e70172.
    PubMed    
    Abstract available
    
    

55. NAITO H, Taoka R, Zhang X, Hossain A, et al
    Enfortumab vedotin promotes PD-L1 expression in urothelial carcinoma via NF-kappaB and STAT3 pathways highlighting mechanisms of immune evasion and potential for combination therapy.
    BMC Immunol. 2025;26:70.
    PubMed    
    Abstract available
    
    

56. LEE S, Jung SY, Kus P, Bondaruk J, et al
    Dysregulated mitochondrial energy metabolism drives the progression of mucosal field effects to invasive bladder cancer.
    J Pathol. 2025 Sep 25. doi: 10.1002/path.6474.
    PubMed    
    Abstract available
    
    

57. SAITO Y, Adomi S, Sakai K, Antonio De Velasco M, et al
    Evaluation of Telomerase Reverse Transcriptase (TERT) Promoter Mutations in Photodynamic Diagnosis With 5-Aminolevulinic Acid False-Positive Sites in Non-muscle-Invasive Bladder Cancer.
    Cureus. 2025;17:e90860.
    PubMed    
    Abstract available
    
    

58. ZHANG L, Zhou L, Xu W, Wu P, et al
    RNA m(5)C Modifications in the Development and Prognosis of Muscle-Invasive Bladder Cancer.
    Mol Carcinog. 2025 Sep 25. doi: 10.1002/mc.70042.
    PubMed    
    Abstract available
    
    

59. ZHANG H, Huang W, Cai Z, Mou S, et al
    CCDC137 knockdown suppresses bladder cancer progression by downregulating SCD.
    J Transl Med. 2025;23:1013.
    PubMed    
    Abstract available
    
    

60. KANG H, Liu X, Ge D, Zeng Y, et al
    Revolutionizing bladder cancer research: Harnessing 3D organoid technology to decode tumor heterogeneity and propel personalized therapeutics.
    Biochim Biophys Acta Rev Cancer. 2025;1880:189454.
    PubMed    
    Abstract available
    
    

61. WANG R, Fernandez K, Zelman B, Speiser J, et al
    Enfortumab vedotin-induced bullous dermatitis.
    Dermatol Online J. 2025;31.
    PubMed    
    Abstract available
    
    

62. AMIN A, Khalatbari F, Cheng L
    Genetic profiling of upper tract urothelial carcinoma: A necessity for precision medicine.
    Expert Rev Mol Diagn. 2025;25:695-708.
    PubMed    
    Abstract available
    
    

63. CITGEZ S, Bulbul E, Ozden SB, Ilki FY, et al
    Benign ureteroenteric anastomotic stricture predictors in radical cystectomy patients: A critical analysis focusing on the nutritional risk index and postoperative urinary tract infection.
    Urol Oncol. 2025 Aug 12:S1078-1439(25)00271.
    PubMed    
    Abstract available
    
    

64. GUAN B, Wang G, Zhang H, Xia M, et al
    Does ureteral stent drainage prior to radical nephroureterectomy increase the risk of intravesical tumor recurrence?
    Urol Oncol. 2025;43:662.
    PubMed    
    Abstract available
    
    

65. NICOLAZZINI M, Longoni M, Falkenbach F, Marmiroli A, et al
    Robot-assisted vs. open radical cystectomy: octogenarians vs. non octogenarians.
    Eur J Surg Oncol. 2025;51:110345.
    PubMed    
    Abstract available
    
    

66. RAUTIOLA J, Bjorklund J, Zelic R, Pellegrino F, et al
    Pelvic lymph-node dissections in bladder and prostate cancer surgery and the risk of postoperative venous thromboembolism.
    Eur J Surg Oncol. 2025;51:110326.
    PubMed    
    Abstract available
    
    

67. JUSTE-ALVAREZ S, Garcia-Rayo Encina C, Gomez Del Canizo C, Hernandez-Arroyo M, et al
    Comparison of prognosis between primary and progressive muscle-invasive bladder carcinoma: A prospective analysis of long-term outcomes after radical cystectomy.
    Actas Urol Esp (Engl Ed). 2025;49:501815.
    PubMed    
    Abstract available
    
    

68. ZHAO M, Zhang P, Xu J, Wang S, et al
    Small cell carcinoma with rhabdomyosarcomatous differentiation of the urinary bladder: an integrated clinicopathological and molecular characterization of five cases.
    Virchows Arch. 2025;487:523-533.
    PubMed    
    Abstract available
    
    

69. NEGISHI T, Kobayashi H, Furubayashi N, Morihara K, et al
    Health-Related Quality of Life in a Real-World Cohort of Patients with Advanced Urothelial Carcinoma Treated with Immune Checkpoint Inhibitors.
    Oncology. 2025;103:921-929.
    PubMed    
    Abstract available
    
    

70. WANG B, Bao EH, Jiang BL, Yang L, et al
    Signal mining and gender differences analysis of adverse events in NMIBC treatment with gemcitabine and BCG bladder instillation based on the FAERS database.
    Expert Opin Drug Saf. 2025;24:1241-1248.
    PubMed    
    Abstract available
    
    

71. CELIK M, Polat ME, Karaaslan M, Odabas O, et al
    Prediction of recurrence using hematologic and urinary markers in intravesical Bacillus calmette Guerin treated bladder cancer.
    Sci Rep. 2025;15:35415.
    PubMed    
    Abstract available
    
    

72. MA TS, He HY
    [The application and advances of immunohistochemistry in the diagnosis and differential diagnosis of bladder tumors].
    Zhonghua Bing Li Xue Za Zhi. 2025;54:1110-1113.
    PubMed    
    
    
    

73. RADIF D, Lindskrog SV, Nordentoft I, Birkenkamp-Demtroder K, et al
    The Impact of Kidney, Liver, and Immune Function on Circulating Tumor DNA Detection in Muscle-invasive Bladder Cancer.
    Eur Urol Oncol. 2025 Oct 9:S2588-9311(25)00246-9. doi: 10.1016/j.euo.2025.
    PubMed    
    Abstract available
    
    

74. COLONNA G, Liesker D, M WB, Taurino M, et al
    Clinical Characteristics and Management of Infective Native Arterial Aneurysms Associated with BCG Therapy for Bladder Cancer.
    Ann Vasc Surg. 2025 Oct 8:S0890-5096(25)00659-4. doi: 10.1016/j.avsg.2025.
    PubMed    
    Abstract available
    
    

75. ITO H, Koyama T, Tanahara S, Toda D, et al
    MRI findings of granulomatous prostatitis induced by intravesical Bacillus Calmette-Guerin treatment for bladder cancer: a comparison with prostate cancer.
    Jpn J Radiol. 2025 Oct 10. doi: 10.1007/s11604-025-01871.
    PubMed    
    Abstract available
    
    

76. TOKUDA PJK, Aizawa R, Iramina H, Ogata T, et al
    Online adaptive radiation therapy for muscle-invasive bladder cancer: short-course and high-precision definitive treatment for elderly or medically fragile patients.
    Jpn J Radiol. 2025 Oct 10. doi: 10.1007/s11604-025-01885.
    PubMed    
    Abstract available
    
    

77. MA Z, Hao Y, He W, Xie X, et al
    Comprehensive investigation identifies CPSF3 as a novel prognostic and oncogenic biomarker in bladder cancer.
    Discov Oncol. 2025;16:1847.
    PubMed    
    Abstract available
    
    

78. ZHANG EZ, Millot JC, Balasubramanian A, Davis L, et al
    Persistent Sex Disparities in Bladder Cancer Diagnosis, an Analysis of National Trends from 2012 to 2021.
    Urol Pract. 2025 Oct 10:101097UPJ0000000000000904.
    PubMed    
    Abstract available
    
    

79. WANG S, Ye D, Yang L, Cheng F, et al
    Distinct Clinicopathological Features of HER2-Negative, HER2-Low, and HER2-Overexpressing Urothelial Carcinoma in a Large Chinese Cohort.
    Cancer Med. 2025;14:e71289.
    PubMed    
    Abstract available
    
    

80. MEYERS HM, Sharma J, Abdellatef AA, You M, et al
    Differential Expression of One-Carbon Pathway Enzyme ALDH1L1 Is Linked to Tumorigenicity of Low-Grade Bladder Cancer Cells Through Metabolic Reprogramming.
    Cancer Med. 2025;14:e71291.
    PubMed    
    Abstract available
    
    

81. KIDESS M, Ebner B, Volz Y, Hermans J, et al
    [Therapy of non-muscle-invasive Bladder Cancer].
    MMW Fortschr Med. 2025;167:40-41.
    PubMed    
    
    
    

82. MOLINA-CERRILLO J, Catto J, Kamat AM, Necchi A, et al
    Revisiting Neoadjuvant Chemotherapy in Cisplatin-eligible Muscle-invasive Bladder Cancer.
    Eur Urol Oncol. 2025 Oct 8:S2588-9311(25)00242-1. doi: 10.1016/j.euo.2025.
    PubMed    
    Abstract available
    
    

83. KAWAHARA T, Nitta S, Shiga M, Nagumo Y, et al
    Second opinions and pathological review impact the clinical management of patients with muscle-invasive bladder cancer.
    World J Urol. 2025;43:602.
    PubMed    
    Abstract available
    
    

84. LIU H, Chen J, Zhu Q, Liu H, et al
    Efficacy of Disitamab Vedotin and Immune Profiles in High-Risk Non-Muscle-Invasive Bladder Cancer With HER2 Overexpression.
    MedComm (2020). 2025;6:e70427.
    PubMed    
    
    
    

85. HUSSAIN H, Reid U, Nagtode S, Shameem F, et al
    Macroplastique, a urethral bulking agent for stress urinary incontinence mimicking a bladder tumour.
    BMJ Case Rep. 2025;18:e263166.
    PubMed    
    Abstract available
    
    

86. 
    RETRACTION: Examining the Causal Association between Psoriasis and Bladder Cancer: A Two-sample Mendelian Randomization Analysis.
    Skin Res Technol. 2025;31:e70252.
    PubMed    
    
    
    

87. SUGINO Y, Bao X, Sekito S, Miyachi S, et al
    Zebrafish Xenograft Model for Predicting Cisplatin Efficacy in Muscle-Invasive Bladder Cancer.
    Cancer Sci. 2025 Oct 8. doi: 10.1111/cas.70217.
    PubMed    
    Abstract available
    
    

88. MAQBOOL A, Aziz W, Iqbal S, Ather MH, et al
    Effectiveness of Video-Based Instructions on Urostomy Self-Care in Patients Undergoing Radical Cystectomy with Ileal Conduit Urinary Diversion.
    J Coll Physicians Surg Pak. 2025;35:1345-1349.
    PubMed    
    Abstract available
    
    

89. TONG H, Sun Y, He W
    Commentary on "Complex causal association between immune cell phenotypes and bladder cancer: a mendelian randomization and mediation study".
    Int J Surg. 2025 Oct 7. doi: 10.1097/JS9.0000000000003587.
    PubMed    
    
    
    

90. DULF DV, Ravegnini G, Giorgi FM, Burnar AL, et al
    The miRNA-immune axis in bladder cancer: systematic evidence for a new era of immunotherapy precision.
    Front Immunol. 2025;16:1639334.
    PubMed    
    Abstract available
    
    

91. MARTINSON T, Hare CB, Kirmaier A, Presti JC, et al
    Disseminated BCGosis After Intravesical BCG Installation for Bladder Cancer.
    Case Rep Infect Dis. 2025;2025:9532859.
    PubMed    
    Abstract available
    
    

92. ZHANG L, Li F, Liu L, Cao J, et al
    Prevalence and prognostic value of sarcopenia in patients with bladder cancer undergoing radical cystectomy: a systematic review and meta-analysis.
    Front Oncol. 2025;15:1642833.
    PubMed    
    Abstract available
    
    

93. GUI Q, Guo H, Liu T, Wen X, et al
    Prognostic risk factors and the role of systemic inflammatory response index in predicting outcomes for non-muscle-invasive bladder cancer.
    Front Oncol. 2025;15:1646723.
    PubMed    
    Abstract available
    
    

94. CHOU KY, Chang AC, Hwang TI, Tsai TF, et al
    ABCC6 Transporter Contributed to Cisplatin Resistance on Bladder Cancer.
    Int J Med Sci. 2025;22:3895-3905.
    PubMed    
    Abstract available
    
    

95. DI Y, Zhang L, Zhao L, Yin L, et al
    Influencing Factors and Risk Prediction Model Construction of Urinary Tract Infections in Patients with Bladder Cancer.
    Res Rep Urol. 2025;17:383-399.
    PubMed    
    Abstract available
    
    

96. PECE A, Lovato G, Cela I, Mercatelli A, et al
    Glycosylated LGALS3BP is highly secreted by bladder cancer cells and represents a novel urinary disease biomarker.
    Mol Oncol. 2025 Oct 5. doi: 10.1002/1878-0261.70140.
    PubMed    
    Abstract available
    
    

97. CHEN AL, Zhang CA, Ogunkeye J, Ge TJ, et al
    Differences in postoperative communication patterns among patients with limited English proficiency following radical cystectomy for bladder cancer.
    Urol Oncol. 2025 Oct 3:S1078-1439(25)00346-1. doi: 10.1016/j.urolonc.2025.
    PubMed    
    Abstract available
    
    

98. MOHAMMADNEJAD F, Rajabi N, Doustvandi MA, Nobari SA, et al
    Photodynamic therapy with zinc phthalocyanine enhances cisplatin sensitivity of human muscle-invasive bladder cancer cells by downregulation of PI3K/AKT/mTOR signaling pathway.
    Cancer Treat Res Commun. 2025;45:101007.
    PubMed    
    Abstract available
    
    

99. LONGONI M, Falkenbach F, Marmiroli A, Le QC, et al
    Effect of neoadjuvant chemotherapy on years of life lost in radical cystectomy-treated T2N0M0 bladder cancer patients.
    World J Urol. 2025;43:591.
    PubMed    
    Abstract available
    
    

100. LOTEM M, Sharkia I, Azria B, Harpenas E, et al
     Urine cf-nucleosomes: A non-invasive window into human physiology and disease.
     Cell Genom. 2025;5:100974.
     PubMed    
     Abstract available
     
     

101. BROUZES H, Ourfali S, Fassi-Fehri H, Benoit-Janin M, et al
     Predicting recurrence and progression in NMIBC: A multi-event and temporal analysis approach.
     Fr J Urol. 2025;35:102921.
     PubMed    
     Abstract available
     
     

102. IIZUKA T, Ishikawa A, Motoi N, Kanda H, et al
     Immunostaining for polycomb group protein EZH2 as a diagnostic tool to differentiate urothelial carcinoma in situ from benign lesions.
     Hum Pathol. 2025;160:105823.
     PubMed    
     Abstract available
     
     

103. DAMAJ N, Naim N, Saad A, Kattan C, et al
     Management of bladder cancer recurrence following the trimodality therapy.
     Front Oncol. 2025;15:1672431.
     PubMed    
     Abstract available
     
     

104. HALAVA V, Tuominen J, Lindholm P, Kyyronen T, et al
     EWSR1::BEND2 fusion sarcoma of the urinary bladder - a case report and review of literature.
     Diagn Pathol. 2025;20:116.
     PubMed    
     Abstract available
     
     

105. HONG JL, Chen C, Liu X, Cristescu R, et al
     Prevalence of therapeutic or disease-relevant oncogenic alterations: An analysis of the AACR Project GENIE Biopharma Cooperative bladder cancer cohort.
     Urol Oncol. 2025 Oct 15:S1078-1439(25)00353.
     PubMed    
     Abstract available
     
     

106. EDER AC, Omrane MA, El Fakiri M, Wielenberg CF, et al
     First-in-Human PET Imaging of MT1-MMP in a Patient with Breast and Muscle-Invasive Urothelial Bladder Cancer Using the Bicyclic Radiotracer [(68)Ga]Ga-BCY25286.
     J Nucl Med. 2025 Oct 16:jnumed.125.269882. doi: 10.2967/jnumed.125.269882.
     PubMed    
     
     
     

107. KUMA Y, Kido-Nakahara M, Kuba-Fuyuno Y, Matsumoto T, et al
     Enfortumab Vedotin-Related Skin Toxicities: Insights From Clinical and Histopathological Analysis.
     J Dermatol. 2025;52:1584-1588.
     PubMed    
     Abstract available
     
     

108. WANG R, Xu Z, Ding Z, Ge J, et al
     Integrated Mendelian randomization analysis reveals causal relationship between LAMA5 and bladder cancer and its metabolic mechanisms.
     Contemp Oncol (Pozn). 2025;29:287-296.
     PubMed    
     Abstract available
     
     

109. BEDORE SR, Shin DH, van der Eerden J, Town MV, et al
     Pembrolizumab-induced myasthenia gravis: A rare immune-related adverse event in a patient treated for bladder cancer.
     Urol Case Rep. 2025;63:103226.
     PubMed    
     Abstract available
     
     

110. JAIME-CASAS S, Yip W, Lama DJ, Goes V, et al
     Clinical Predictors and Prognostic Significance of Pathologic Disease Upstaging at Radical Cystectomy in Patients with Muscle-Invasive Bladder Cancer.
     Cancers (Basel). 2025;17:3265.
     PubMed    
     Abstract available
     
     

111. ALBERS ACOSTA E, Pelari Mici L, Guemez CM, Velasco Balanza C, et al
     Beyond Visualization: Advanced Imaging, Theragnostics and Biomarker Integration in Urothelial Bladder Cancer.
     Cancers (Basel). 2025;17:3261.
     PubMed    
     Abstract available
     
     

112. DEL GIUDICE F, Santarelli V, Spurna K, Ali Kirmani SG, et al
     Contemporary Trends and Predictors of pT0 in Radical Cystectomy Specimens Among Non-Muscle and Muscle-Invasive Bladder Cancer Patients: A Propensity Score-Matched Analysis from a Single Tertiary Centre in the United Kingdom.
     Cancers (Basel). 2025;17:3110.
     PubMed    
     Abstract available
     
     

113. LEVY J, Sakatani T, Murakami K, Kita Y, et al
     Comparative Analysis of CT and MRI Combined with RNA Sequencing for Radiogenomic Staging of Bladder Cancer.
     Int J Mol Sci. 2025;26:9570.
     PubMed    
     Abstract available
     
     

114. SPIRITO L, Tammaro S, Coppola P, Manfredi C, et al
     Association Between Baseline Neutrophil-to-Lymphocyte Ratio and Short-Term Urinary Quality of Life During BCG Induction in Male Patients with Non-Muscle-Invasive Bladder Cancer: A Prospective Observational Study.
     J Clin Med. 2025;14:6908.
     PubMed    
     Abstract available
     
     

115. QI W, Qisheng L, Weiyang W, Yuan L, et al
     Integrating urinary dual-gene methylation and VI-RADS score to predict residual tumors after TURBT in NMIBC: a nomogram-based model.
     BMC Urol. 2025;25:255.
     PubMed    
     Abstract available
     
     

116. ZHU X, Yin X, Niu L, Yang G, et al
     Cerium oxide-embedded gold nanoparticles loaded with astragaloside IV for bladder cancer therapy.
     Sci Rep. 2025;15:36067.
     PubMed    
     Abstract available
     
     

117. ZUO M, Liao Y, He P, Zhu Y, et al
     p53 and PD-1/PD-L1 expression contribute to disease progression and are correlated to immune infiltrates in urothelial carcinoma.
     Sci Rep. 2025;15:36072.
     PubMed    
     Abstract available
     
     

118. IBRAHIM D, Abdelghaffar A, Nabil Hassan EE
     Added value of delayed imaging after diuretic injection in evaluation of cases of bladder cancer with PET.
     Nucl Med Commun. 2025 Oct 15. doi: 10.1097/MNM.0000000000002056.
     PubMed    
     Abstract available
     
     

119. HUANG M
     Global burden and inequalities of bladder cancer attributable to high fasting plasma glucose: Trends 1990-2021 and Projections to 2040.
     Medicine (Baltimore). 2025;104:e45255.
     PubMed    
     Abstract available
     
     

120. SCHOLTE R, Hinrichs C
     Bladder carcinoma in a bladder diverticulum: a case report.
     J Med Case Rep. 2025;19:508.
     PubMed    
     Abstract available
     
     

121. CHANG Z, Wang J, Wang L, Hu Z, et al
     Circulating metabolites and bladder cancer: a Mendelian randomization and multi-omics study.
     Discov Oncol. 2025;16:1859.
     PubMed    
     Abstract available
     
     

122. MANSOUR R, Tarhini F, Bruce N, Blanche J, et al
     In vitro assessment of benzothiadiazole-based photoactive polymers against ovarian, prostate and bladder cancer cell lines for photodynamic therapy.
     Discov Oncol. 2025;16:1863.
     PubMed    
     Abstract available
     
     

123. ANCESCHI U, Basile S, Amparore D, Di Maida F, et al
     "Far beyond the shape": an early head-to-head comparative urodynamic analysis of three contemporary totally intracorporeal robotic orthotopic neobladder techniques.
     J Robot Surg. 2025;19:689.
     PubMed    
     Abstract available
     
     

124. YANG T, Guo L, Kong S, Xu Q, et al
     The lncRNA MIR4435-2HG Modulates Bladder Cancer Progression and Ferroptosis Through the IQGAP3/Ras/ERK/CREB Pathway.
     FASEB J. 2025;39:e71119.
     PubMed    
     Abstract available
     
     

125. HADZIOSMANOVIC O, Kulovac B, Valjevac A, Fajkic A, et al
     Influence of Glutathione S-transferase Mu 1 (GSTM1), Glutathione S-transferase Theta 1 (GSTT1), and N-acetyltransferase 2 (NAT2) Variants on Bladder Cancer Progression and Recurrence Rating: A Bosnian and Herzegovinian Case-Control Study.
     Cureus. 2025;17:e91948.
     PubMed    
     Abstract available
     
     

126. POWER N
     Guideline adherence in treating non-muscle-invasive bladder cancer: Discipline can save lives.
     Can Urol Assoc J. 2025;19:311.
     PubMed    
     
     
     

127. CHEN Y, Yu Q, Jiang X, Li L, et al
     Identifying the causal role and therapeutic potential of immune-related genes in bladder cancer: a Mendelian randomization study.
     Discov Oncol. 2025;16:1857.
     PubMed    
     Abstract available
     
     

128. FURUHATA A, Teramoto Y, Minamiguchi S, Hirata M, et al
     Neutrophil-calibrated atypical squamous cells in ThinPrep urine cytology for detecting squamous differentiation in urothelial carcinoma.
     Cancer Cytopathol. 2025;133:e70055.
     PubMed    
     Abstract available
     
     

129. LI F, Wang D, Gao Y, Cui Y, et al
     Bladder cancer immunotherapy parallel advances in BCG optimization and next-generation vaccine platforms.
     Front Immunol. 2025;16:1648698.
     PubMed    
     Abstract available
     
     

130. ROCHA JM, Fernandes R, Queiros L, Rodrigues J, et al
     Therapy-Related Toxicity in Bladder Cancer Treatment: A Case Report.
     Cureus. 2025;17:e91905.
     PubMed    
     Abstract available
     
     

131. YU ZJ, Xu XD, Zou XC, Su P, et al
     Ensemble machine learning models for predicting bone metastasis in bladder cancer.
     Front Oncol. 2025;15:1653506.
     PubMed    
     Abstract available
     
     

132. LISSON CG, Gallee L, Muller K, Manoj S, et al
     Machine learning-based radiomics for bladder cancer staging: evaluating the role of imaging timing in differentiating T2 from T3 disease.
     Front Oncol. 2025;15:1591742.
     PubMed    
     Abstract available
     
     

133. LI R, Hensley PJ, Babjuk M, Bukavina L, et al
     Intermediate-risk Non-muscle-invasive Bladder Cancer: Recommendations for Definitions, Risk Stratification, Management Strategies, and Clinical Trial Design from the International Bladder Cancer Group.
     Eur Urol Oncol. 2025 Oct 10:S2588-9311(25)00223.
     PubMed    
     Abstract available
     
     

134. LONG Z, Feng S, Xu Y, Yu J, et al
     Multi-parameter precise molecular profiling of bladder cancer based on aptamer probe package.
     Talanta. 2025;298.
     PubMed    
     Abstract available
     
     

135. PRASAD SM, Louie MJ, Burger B, Tsurutis V, et al
     Pharmacokinetics of UGN?102, an investigational mitomycin?containing reverse thermal gel for the treatment of non-muscle invasive bladder cancer.
     Cancer Chemother Pharmacol. 2025;95:100.
     PubMed    
     Abstract available
     
     

136. LEI J, Wang P, Qu Y, Wang X, et al
     Identification of TRIM59 as a Key Biomarker for Ferroptosis Resistance and Immunotherapy Response in Bladder Cancer via Multi-Omics Integration and Machine Learning.
     Front Biosci (Landmark Ed). 2025;30:44395.
     PubMed    
     Abstract available
     
     

137. MENG Y, Zhang S, Aout M, Babcock A, et al
     Cost-effectiveness of enfortumab vedotin plus pembrolizumab as a first-line treatment of locally advanced or metastatic urothelial carcinoma in the United States.
     J Med Econ. 2025;28:1779-1797.
     PubMed    
     Abstract available
     
     

138. ZHAO T, Akgul M, Siegmund SE
     Clinicopathologic, immunohistochemical and genomic characterization of urothelial carcinoma with myxoid and chordoid features.
     Histopathology. 2025;87:757-767.
     PubMed    
     Abstract available
     
     

139. SHEN R, Jiang F, Huang X, Hong G, et al
     Artificial Intelligence-Assisted Urine Cytology for Noninvasive Detection of Muscle-Invasive Urothelial Carcinoma: A Multi-Center Diagnostic Study with Prospective Validation.
     Adv Sci (Weinh). 2025;12:e08977.
     PubMed    
     Abstract available
     
     

140. REIS H, Al-Ahmadie H, Gaisa NT, Lopez-Beltran A, et al
     The Dublin International Society of Urological Pathology (ISUP) Consensus Conference on Best Practice Recommendations on the Pathology of Urachal Neoplasms.
     Am J Surg Pathol. 2025;49:e18-e26.
     PubMed    
     Abstract available
     
     

141. CHEN J, Daniels E, Mirsadraei L, Skala SL, et al
     Clinicopathologic Review of Malignancies in Neobladders and Conduits Following Bladder Reconstruction.
     Am J Surg Pathol. 2025;49:1150-1157.
     PubMed    
     Abstract available
     
     

142. DOWNES MR, Lajkosz K, Algaba F, Allory Y, et al
     Interobserver reproducibility of a hybrid three-tier grading system of papillary nonmuscle invasive urothelial carcinoma: an international Uropathology study.
     Histopathology. 2025;87:649-659.
     PubMed    
     Abstract available
     
     

143. PARK I, Yoon S, Kim I, Park K, et al
     Pemetrexed Maintenance versus Observation in Patients with Advanced Urothelial Carcinoma Who Completed First-Line Platinum-Based Chemotherapy without Disease Progression (PREMIER, KCSG GU16-05).
     Cancer Res Treat. 2025;57:1167-1177.
     PubMed    
     Abstract available
     
     

144. DE ANGELIS M, Siech C, Di Bello F, Rodriguez Penaranda N, et al
     Survival Rates in Trimodal Therapy Versus Radiotherapy in Urothelial Carcinoma of Urinary Bladder.
     Eur Urol Focus. 2025;11:251-257.
     PubMed    
     Abstract available
     
     

145. FINATI M, Russo P, Pradere B
     Comment on: "Enhanced prognostic value of four-tier hybrid grading system in Ta non-muscle-invasive bladder cancer".
     Minerva Urol Nephrol. 2025;77:724-726.
     PubMed    
     
     
     

146. PALUMBO S, Ferro M, Pandolfo SD, Romano L, et al
     Comment on: "The grade of systemic inflammation, immune inhibition, and gut dysbiosis as prognostic factors for bladder cancer recurrence: a metabolomics approach".
     Minerva Urol Nephrol. 2025;77:721-723.
     PubMed    
     
     
     

147. LASORSA F, Ditonno P, Lucarelli G
     Comment on: "The current role of photodynamic diagnosis (PDD) in the management of non-muscle invasive bladder cancer: the Italian Society of Urology (SIU) Position Paper".
     Minerva Urol Nephrol. 2025;77:718-720.
     PubMed    
     
     
     

148. PANDOLFO SD, Mir MC, Cerrato C, Russo P, et al
     From vintage to vanguard: has chemoablation's prime time finally arrived in bladder cancer treatment?
     Minerva Urol Nephrol. 2025;77:573-575.
     PubMed    
     
     
     

149. ASSI A, Jalbout J, Youssef B, Diab E, et al
     BlaCancer: a mobile health solution for enhancing bladder cancer care.
     BMC Urol. 2025;25:262.
     PubMed    
     Abstract available
     
     

150. KARAKANLI MU, Kutluturk EG, Polat EC, Otunctemur A, et al
     Diagnostic value of serum DR-70 levels, a new fibrin-related biomarker, in bladder cancer patients.
     BMC Urol. 2025;25:264.
     PubMed    
     Abstract available
     
     

151. BARENTSZ J, van Koeverden SW, van der Leest M
     VI-RADS is not enough: why image quality is the key to reliable bladder cancer staging.
     Eur Radiol. 2025 Oct 22. doi: 10.1007/s00330-025-12086.
     PubMed    
     
     
     

152. BOILLAT S, Goasmat V, Derre L, Domingos-Pereira S, et al
     Corrigendum to "Role of myeloid-derived suppressor cells in bladder cancer and targeted therapeutic strategies" [Gene 970 (2025) 149772].
     Gene. 2025 Oct 21:149839. doi: 10.1016/j.gene.2025.149839.
     PubMed    
     
     
     

153. POWLES T, Kann AG, Castellano D, Gross-Goupil M, et al
     ctDNA-Guided Adjuvant Atezolizumab in Muscle-Invasive Bladder Cancer.
     N Engl J Med. 2025 Oct 20. doi: 10.1056/NEJMoa2511885.
     PubMed    
     Abstract available
     
     

154. BADHEEB AM, Alkhanbash O, Alzubaidi Q, Al Asmari A, et al
     Survival outcomes and prognostic factors in muscle-invasive bladder cancer: a retrospective cohort study from a Saudi Arabian tertiary center.
     Arch Ital Urol Androl. 2025 Oct 22:14119. doi: 10.4081/aiua.2025.14119.
     PubMed    
     Abstract available
     
     

155. MANDANACH C, Handra CM, Rascu A, Hohor S, et al
     Occupational hazards and bladder cancer-An umbrella review of the risk in workers exposed over the past 30 years.
     Front Public Health. 2025;13:1667873.
     PubMed    
     Abstract available
     
     

156. GONG YQ, Peng D, Ning XH, Yang XY, et al
     Erratum: [Corrigendum] UBE2T silencing suppresses proliferation and induces cell cycle arrest and apoptosis in bladder cancer cells.
     Oncol Lett. 2025;30:580.
     PubMed    
     Abstract available
     
     

157. LIU Z, Yu L, Yan F, Qi J, et al
     National and subnational trends of years of life lost and reduced life expectancy caused by bladder cancer in China from 2005 to 2020.
     BMC Public Health. 2025;25:3553.
     PubMed    
     Abstract available
     
     

158. 
     Intravesical gemcitabine (Inlexzo) for bladder cancer.
     Med Lett Drugs Ther. 2025;67:e176-e177.
     PubMed    
     
     
     

159. CINAR NB, Yilmaz H, Tasyurek EY, Kurt Pehlivanoglu M, et al
     Evaluation of inflammatory markers in survival analysis of patients undergoing radical cystectomy using machine learning.
     World J Urol. 2025;43:620.
     PubMed    
     Abstract available
     
     

160. NECCHI A, Briganti A, Montorsi F
     Front-line durvalumab and BCG in the treatment of non-muscle-invasive bladder cancer.
     Lancet. 2025 Oct 17:S0140-6736(25)02015-X. doi: 10.1016/S0140-6736(25)02015.
     PubMed    
     
     
     

161. DE SANTIS M, Palou Redorta J, Nishiyama H, Krawczynski M, et al
     Durvalumab in combination with BCG for BCG-naive, high-risk, non-muscle-invasive bladder cancer (POTOMAC): final analysis of a randomised, open-label, phase 3 trial.
     Lancet. 2025 Oct 17:S0140-6736(25)01897-5. doi: 10.1016/S0140-6736(25)01897.
     PubMed    
     Abstract available
     
     

162. RESEARCH INTERNATIONAL B
     RETRACTION: Downregulation of Long Noncoding RNA LUCAT1 Suppresses the Migration and Invasion of Bladder Cancer by Targeting miR-181c-5p.
     Biomed Res Int. 2025;2025:9842795.
     PubMed    
     Abstract available
     
     

163. REN Q, Li Y, Chen H, Chen Y, et al
     Prognostic value of lymphocyte to monocyte ratio for the patients with bladder cancer: a systematic review and meta-analysis.
     Front Oncol. 2025;15:1601040.
     PubMed    
     Abstract available
     
     

164. SODERKVIST K, Haggstrom C, Hagberg O, Aljabery F, et al
     Calendar time trends in synchronous metastatic urinary bladder cancer before and after the introduction of immune checkpoint inhibitors: a nation-wide population-based cohort study.
     Front Oncol. 2025;15:1680916.
     PubMed    
     
     
     

165. MANDAL S
     Critical appraisal of a meta-analysis on pelvic lymph node dissection in muscle-invasive bladder cancer.
     Indian J Urol. 2025;41:321-322.
     PubMed    
     
     
     

166. ZHANG Z, Yuan C, Ge Q, Cao D, et al
     Bavachalcone targets transferrin receptor and sensitizes gemcitabine to affect bladder cancer progression.
     Imeta. 2025;4:e70071.
     PubMed    
     Abstract available
     
     

167. ZHONG X, Xiao M, Su F, Shi J, et al
     OTUB1 Promotes Stem-like Properties in Bladder Cancer by Stabilising SLC7A11 and Suppressing Ferroptosis through Deubiquitination.
     Arch Esp Urol. 2025;78:1072-1080.
     PubMed    
     Abstract available
     
     

168. KOSEOGLU H, Yalcin B, Eroglu T, Yucetas U, et al
     Qualitative Interferon-gamma Release Assay for Predicting Response to BCG Instillations in Bladder Cancer.
     Arch Esp Urol. 2025;78:1015-1021.
     PubMed    
     Abstract available
     
     

169. BALLESTERO R, Alonso E, Garcia N, Garcia J, et al
     Impact of COVID-19 on Postoperative Complications in Minimal Invasive Radical Cystectomy: A Comprehensive Complication Index-Based Analysis.
     Arch Esp Urol. 2025;78:975-985.
     PubMed    
     Abstract available
     
     

170. MATHIEU R, Evanguelos X, Pierre Etienne G, Yves A, et al
     French recommendations of the AFU Oncology Committee FOR bladder Cancer: update 2025.
     Fr J Urol. 2025 Oct 17:103011. doi: 10.1016/j.fjurol.2025.103011.
     PubMed    
     Abstract available
     
     

171. MEEKS JJ, Powles T
     Combination with BCG induction and maintenance therapy for high-risk non-muscle invasive bladder cancer.
     Ann Oncol. 2025 Oct 17:S0923-7534(25)04962-2. doi: 10.1016/j.annonc.2025.
     PubMed    
     
     
     

172. ROUPRET M, Bertaut A, Pignot G, Neuzillet Y, et al
     ALBAN (GETUG-AFU 37): A phase 3, randomized, open-label, international trial of intravenous atezolizumab and intravesical Bacillus Calmette-Guerin (BCG) versus BCG alone in BCG-naive high-risk, non-muscle invasive bladder cancer (NMIBC).
     Ann Oncol. 2025 Dec 31:S0923-7534(25)04787-8. doi: 10.1016/j.annonc.2025.
     PubMed    
     Abstract available
     
     

173. ZHU G, Tan C, Li Y
     Multi-omics integrative analysis of the mechanisms linking environmental pollutant exposure to bladder cancer pathogenesis.
     Ecotoxicol Environ Saf. 2025;305:119251.
     PubMed    
     Abstract available
     
     

174. LI JM, Liu SM, Zhong MX, Wang L, et al
     Systematic review and meta-analysis of comparing open and robotic-assisted intracorporeal radical cystectomy: based on randomized controlled trials.
     J Robot Surg. 2025;19:700.
     PubMed    
     Abstract available
     
     

175. WESTHOFEN T, Eismann L, Schulz GB, Bauer RM, et al
     Gender Disparities in Health-related Quality of Life Outcomes Following Radical Cystectomy for Bladder Cancer.
     Eur Urol Focus. 2025 Oct 16:S2405-4569(25)00257.
     PubMed    
     Abstract available
     
     

176. KEAM SJ
     Mitomycin Intravesical Solution: First Approval.
     Clin Drug Investig. 2025;45:909-913.
     PubMed    
     Abstract available
     
     

177. KIM CH, Kim S, Kang YH, Kim S, et al
     Association between long-term exposure to a mixture of ambient air pollutants and the incidences of bladder and kidney cancers.
     Environ Res. 2025;285.
     PubMed    
     Abstract available
     
     

178. GUERRERO C, Casal M, Alierta C, Moreo E, et al
     NK cells mediate preventive efficacy of intravenous BCG against lung metastasis in mice.
     Cancer Gene Ther. 2025;32:1090-1097.
     PubMed    
     Abstract available
     
     

179. TZELVES L, Day E, Bhudia A, Markov M, et al
     Organ-sparing robotic-assisted radical cystectomy in men: description of technique and outcomes.
     Minerva Urol Nephrol. 2025;77:700-707.
     PubMed    
     Abstract available
     
     

180. NISHIO K, Hirosuna K, Uchimoto T, Niigawa H, et al
     Real-world Outcomes of Enfortumab Vedotin in Elderly Patients With Metastatic Urothelial Carcinoma.
     Anticancer Res. 2025;45:4575-4583.
     PubMed    
     Abstract available
     
     

181. RUBIO-BRIONES J, Guerrero Ramos F, Mercade Sanchez A, Bezana Abadia I, et al
     External validation of the Uromonitor(R)-version 2 urine test as a biomarker for optimisation of non-muscle-invasive bladder cancer management.
     BJU Int. 2025 Oct 1. doi: 10.1111/bju.70010.
     PubMed    
     Abstract available
     
     

182. BRANDT SB, Korner SK, Milling RV, Nielsen NK, et al
     Ureteroenteric strictures following retrosigmoid vs. conventional ileal conduit - The MOSAIC study (The DaBlaCa-16 study).
     BJU Int. 2025;136:858-865.
     PubMed    
     Abstract available
     
     

183. MASTROIANNI R, Chiacchio G, Tuderti G, Brassetti A, et al
     Stapled vs totally handsewn robotic intracorporeal neobladder: perioperative and functional outcomes.
     BJU Int. 2025;136:866-871.
     PubMed    
     Abstract available
     
     

184. MCELREE IM, Steinberg RL, Hougen HY, Mott SL, et al
     Long-term outcomes of a cascading salvage strategy for high-risk non-muscle-invasive bladder cancer.
     BJU Int. 2025 Oct 22. doi: 10.1111/bju.70044.
     PubMed    
     Abstract available
     
     

185. WU J, Cheng B, Song Y, Cheng J, et al
     Targeting Sialylation Enhances the Therapeutic Efficacy of the Nectin-4-Targeted Antibody-Drug Conjugate Enfortumab Vedotin in Bladder Cancer.
     Cancer Res. 2025 Oct 9. doi: 10.1158/0008-5472.CAN-25-0024.
     PubMed    
     Abstract available
     
     

186. HEISS BL, Chang E, Joeng HK, Fiero MH, et al
     FDA Approval Summary: Nogapendekin Alfa Inbakicept-pmln with BCG for BCG-Unresponsive Carcinoma In Situ.
     Clin Cancer Res. 2025;31:4223-4229.
     PubMed    
     Abstract available
     
     

187. LIU Z, Zhang L, Jin K, Zeng H, et al
     ARID1A Loss plus CD8+ T-Cell Infiltration Associate with Favorable Clinical Outcomes in Urothelial Carcinoma.
     Clin Cancer Res. 2025;31:4311-4322.
     PubMed    
     Abstract available
     
     

188. PRADERE B, Schuit M, Guerrero-Ramos F, Shariat SF, et al
     Side effect management and procedural best practices with indwelling intravesical drug-releasing systems in the treatment of bladder cancer: recommendations from expert panels.
     Curr Opin Urol. 2025 Oct 8. doi: 10.1097/MOU.0000000000001350.
     PubMed    
     Abstract available
     
     

189. STOCKEM CF, van Dorp J, van Dijk N, Vis DJ, et al
     Final clinical analysis of pre-operative ipilimumab and nivolumab in locally advanced urothelial cancer and exploration of tumor-draining lymph node composition: The NABUCCO trial.
     Eur J Cancer. 2025;229:115731.
     PubMed    
     Abstract available
     
     

190. SHI Z, Yang S, Yang Y
     Re: Thomas Dreyer, Simone Brandt, Knud Fabrin, et al. Use of the Xpert Bladder Cancer Monitor Urinary Biomarker Test for Guiding Cystoscopy in High-grade Non-muscle-invasive Bladder Cancer: Results from the Randomized Controlled DaBlaCa-15 Trial. Eur
     Eur Urol. 2025 Sep 27:S0302-2838(25)04682-2. doi: 10.1016/j.eururo.2025.
     PubMed    
     
     
     

191. ROVIELLO G, Antonuzzo L
     Re: Ruben Raychaudhuri, Ali Raza Khaki, Mary W. Redman, et al. Neoadjuvant Pembrolizumab and Accelerated Methotrexate, Vinblastine, Doxorubicin, and Cisplatin in Nonurothelial Histologic Subtypes of Muscle-invasive Bladder Cancer: A Phase 2 Trial. Eur
     Eur Urol. 2025 Sep 27:S0302-2838(25)04695-0. doi: 10.1016/j.eururo.2025.
     PubMed    
     
     
     

192. DREYER T, Jensen JB
     Reply to Heidi Pharo, Hege Marie Vedeld, Rolf Wahlqvist, and Guro E. Lind's Letter to the Editor re: Thomas Dreyer, Simone Brandt, Knud Fabrin, et al. Use of the Xpert Bladder Cancer Monitor Urinary Biomarker Test for Guiding Cystoscopy in High-grade
     Eur Urol. 2025 Sep 25:S0302-2838(25)04642-1. doi: 10.1016/j.eururo.2025.09.4129.
     PubMed    
     
     
     

193. PHARO H, Vedeld HM, Wahlqvist R, Lind GE, et al
     Re: Thomas Dreyer, Simone Brandt, Knud Fabrin, et al. Use of the Xpert Bladder Cancer Monitor Urinary Biomarker Test for Guiding Cystoscopy in High-grade Non-muscle-invasive Bladder Cancer: Results from the Randomized Controlled DaBlaCa-15 Trial. Eur
     Eur Urol. 2025 Sep 24:S0302-2838(25)04646-9. doi: 10.1016/j.eururo.2025.
     PubMed    
     
     
     

194. LI X, Wang X, Zhang G
     Re: Ruben Raychaudhuri, Ali Raza Khaki, Mary W. Redman, et al. Neoadjuvant Pembrolizumab and Accelerated Methotrexate, Vinblastine, Doxorubicin, and Cisplatin in Nonurothelial Histologic Subtypes of Muscle-invasive Bladder Cancer: A Phase 2 Trial. Eur
     Eur Urol. 2025 Sep 24:S0302-2838(25)04654-8. doi: 10.1016/j.eururo.2025.
     PubMed    
     
     
     

195. BELLMUNT J, Powles T, Park SH, Voog E, et al
     Avelumab First-line Maintenance for Advanced Urothelial Carcinoma: Long-term Outcomes from the JAVELIN Bladder 100 Trial in Patients with Nonvisceral or Lymph Node-only Disease.
     Eur Urol. 2025;88:331-338.
     PubMed    
     Abstract available
     
     

196. GALSKY MD, van der Heijden MS, Powles T, Claps M, et al
     Characterization of Patients with Lymph Node Only Metastatic Urothelial Carcinoma Treated with Nivolumab Plus Gemcitabine-Cisplatin Versus Gemcitabine-Cisplatin Alone from the CheckMate 901 Trial.
     Eur Urol. 2025;88:325-330.
     PubMed    
     Abstract available
     
     

197. DANESHMAND S, Zaucha R, Catto JWF, Tran B, et al
     Erdafitinib in Patients with High- and Intermediate-risk Non-muscle-invasive Bladder Cancer: Final Analysis of THOR-2 Study.
     Eur Urol. 2025 Oct 7:S0302-2838(25)04702-5. doi: 10.1016/j.eururo.2025.09.4152.
     PubMed    
     Abstract available
     
     

198. KWONG JCC, Al-Daqqaq Z, Chelliahpillai Y, Lee S, et al
     Development and International Evaluation of an Artificial Intelligence-based Model (PROGRxN-BCa) Using the World Health Organization 2004/2022 Grading System to Predict Progression Risk and Improve Substratification for Non-muscle-invasive Bladder Can
     Eur Urol. 2025 Oct 7:S0302-2838(25)04688-3. doi: 10.1016/j.eururo.2025.09.4145.
     PubMed    
     Abstract available
     
     

199. MEGHANI K, Yu Y, Frydenlund N, Li EZ, et al
     Genomic and Transcriptomic Profiling of High-risk Bladder Cancer Reveals Diverse Molecular and Microenvironment Ecosystems.
     Eur Urol. 2025 Oct 6:S0302-2838(25)04677-9. doi: 10.1016/j.eururo.2025.09.4138.
     PubMed    
     Abstract available
     
     

200. BUISAN O, Servian P, Pedreno-Lopez S, Pages J, et al
     A Novel Heterologous Prime-boost Strategy Using RUTI Vaccine to Improve the Bacillus Calmette-Guerin Response in Non-muscle-invasive Bladder Cancer Patients: Phase 1 RUTIVAC-1 Trial.
     Eur Urol. 2025 Oct 14:S0302-2838(25)00505-6. doi: 10.1016/j.eururo.2025.
     PubMed    
     Abstract available
     
     

201. CHU CE, Chen Z, Whiting K, Ostrovnaya I, et al
     Clinical Outcomes, Genomic Heterogeneity, and Therapeutic Considerations Across Histologic Subtypes of Urothelial Carcinoma.
     Eur Urol. 2025;88:472-481.
     PubMed    
     Abstract available
     
     

202. DE WIT R, Vaughn DJ, Fradet Y, Fong L, et al
     Impact of Prior Chemotherapy on Response to Second-line Pembrolizumab in Urothelial Cancer: Exploratory Analysis of the Phase 3 KEYNOTE-045 Trial.
     Eur Urol. 2025;88:462-471.
     PubMed    
     Abstract available
     
     

203. JAZAYERI B, Wang X, Li R
     Re: Thomas Dreyer, Simone Brandt, Knud Fabrin, et al. Use of the Xpert Bladder Cancer Monitor Urinary Biomarker Test for Guiding Cystoscopy in High-grade Non-muscle-invasive Bladder Cancer: Results from the Randomized Controlled DaBlaCa-15 Trial. Eur
     Eur Urol. 2025 Oct 16:S0302-2838(25)04729-3. doi: 10.1016/j.eururo.2025.09.4168.
     PubMed    
     
     
     

204. FU MZ, Ghodoussipour S, Packiam VT
     The Future of Bladder Preservation for Muscle-invasive Bladder Cancer.
     Eur Urol. 2025 Oct 16:S0302-2838(25)04734-7. doi: 10.1016/j.eururo.2025.09.4173.
     PubMed    
     
     
     

205. TANG Y, Han Z, Yi X, Li J, et al
     Survival improvements and disparities in metastatic prostate adenocarcinoma, clear cell renal cell carcinoma, and urothelial carcinoma of bladder.
     Int J Cancer. 2025;157:2485-2494.
     PubMed    
     Abstract available
     
     

206. INOUE S, Hayakawa A, Kobayashi M, Nagasaka Y, et al
     Response to First-Line Chemotherapy Predicts Response to Maintenance Avelumab Therapy in Japanese Patients With Advanced Urothelial Carcinoma.
     Int J Urol. 2025;32:1449-1459.
     PubMed    
     Abstract available
     
     

207. AKPINAR C, Erkartal S, Soydas T, Demirel D, et al
     Decision Curve Analysis-Based Risk-Adaptive Strategy for Individualizing Cystoscopy Decisions in Patients With Primary Microscopic Hematuria.
     Int J Urol. 2025;32:1395-1402.
     PubMed    
     Abstract available
     
     

208. KUKIMOTO T, Nakamura Y, Hata S, Shimada H, et al
     Expression of Glucocorticoid Receptor Beta in Bladder Cancer and Its Clinicopathological Significance: A Novel Diagnostic Marker to Predict Progression and Recurrence of Cancer.
     Int J Urol. 2025 Oct 15. doi: 10.1111/iju.70254.
     PubMed    
     Abstract available
     
     

209. YENTUR S, Canitez IO, Dusunus YE, Sahin S, et al
     Simultaneous transurethral resection of the prostate and bladder tumor: a safety and efficacy analysis.
     Int Urol Nephrol. 2025;57:3219-3226.
     PubMed    
     Abstract available
     
     

210. ZHANG T, Liu J, Feng L, Ke C, et al
     Prognostic prediction of incidental prostate cancer in radical cystoprostatectomy for muscle-invasive bladder cancer.
     Int Urol Nephrol. 2025 Oct 23. doi: 10.1007/s11255-025-04858.
     PubMed    
     Abstract available
     
     

211. BANDARI J, Messing EM
     Single-Arm Pivotal Studies in Bacillus Calmette-Guerin-Unresponsive Non-Muscle-Invasive Bladder Cancer.
     J Clin Oncol. 2025 Oct 21:JCO2501893. doi: 10.1200/JCO-25-01893.
     PubMed    
     
     
     

212. MEEKS JJ, van der Heijden MS, Powles T, Galsky MD, et al
     PD37-09 The First Report Of Disease-Free Survival Analyses From The Niagara Trial Of Perioperative Durvalumab Plus Neoadjuvant Chemotherapy In Muscle-Invasive Bladder Cancer: Erratum.
     J Urol. 2025;214:556.
     PubMed    
     
     
     

213. DONAHUE TF, Assel M, Cha EK, Goh A, et al
     Evaluating Benefits of Peristomal Mesh Placement at the Time of Radical Cystectomy and Ileal Conduit Formation: A Phase 3, Randomized Controlled Trial.
     J Urol. 2025;214:487-495.
     PubMed    
     Abstract available
     
     

214. ZHU D, Wan X, Huang H, Chen X, et al
     [Expression of Concern] Knockdown of Bmi1 inhibits the stemness properties and tumorigenicity of human bladder cancer stem cell?like side population cells.
     Oncol Rep. 2026;55:1.
     PubMed    
     Abstract available
     
     

215. NAKANISHI Y, Nakanishi Y, Ogasawara RA, Imasato N, et al
     Separated Transfixing Uretero-Enteral Anastomosis Method in Robot-Assisted Radical Cystectomy with Ileal Conduit: Early Induction Experience.
     Urol Int. 2025;109:546-552.
     PubMed    
     Abstract available
     
     

216. BAHLBURG H, Bahlburg H, Rausch P, Silberg M, et al
     Stage Migration in Urological Cancers in Germany during the COVID-19 Pandemic: Fact or Fiction?
     Urol Int. 2025;109:501-507.
     PubMed    
     Abstract available
     
     

217. PATTOU M, Ochoa A, Goujon A, Verine J, et al
     Outpatient Transurethral Resections of Bladder Tumors: Insights from the Largest Cohort to Date.
     Urol Int. 2025;109:471-477.
     PubMed    
     Abstract available
     
     

218. GALLARDO ZAMORA L, Hohage J, Degener S, Dotse J, et al
     Cancer Reporting Protocols in transurethral resection of bladder tumor (TURBT) - standardized reporting of bladder cancer and improvement of communication between pathologists and urologists.
     Urol Int. 2025 Oct 16:1-13. doi: 10.1159/000548723.
     PubMed    
     Abstract available
     
     

219. 
     Expression of Concern: "Letter to the Editor on "Early Adjuvant Chemotherapy Improves Survival in Muscle Invasive Bladder Cancer: A Systematic Review and Meta-analysis"" [Urology, volume 199, 2025, 259-260].
     Urology. 2025;204:370.
     PubMed    
     
     
     

220. REZAEE ME, Mahon KM, Su ZT, Luck KM, et al
     Characterizing Symptoms and Defining Toxicity in Ambulatory Transurethral Resection of Bladder Tumor: Results From a Multicenter Prospective Cohort Study.
     Urology. 2025;204:1-8.
     PubMed    
     Abstract available
     
     

221. LEE MS, Moschini M, Britton CJ, Longoni M, et al
     Development and External Validation of a Local Pelvic Recurrence Risk Score After Radical Cystectomy: Identifying the Ideal Candidate for Adjuvant Radiation Clinical Trials.
     Urology. 2025;204:143-150.
     PubMed    
     Abstract available
     
     

222. CHEN B, Zhou Y, Li Z, Chen J, et al
     A study on predicting recurrence of non-muscle-invasive bladder cancer within 2 years using mp-MRI radiomics.
     BMC Cancer. 2025;25:1497.
     PubMed    
     
     
     

223. LIU S, Lei K, Li G, Zheng P, et al
     The integration of transcriptomics and metabolomics elucidates the antitumor mechanisms of mycophenolic acid in bladder cancer cells.
     BMC Cancer. 2025;25:1463.
     PubMed    
     Abstract available
     
     

224. YEH CC, Tsai PC, Song YD, Low YS, et al
     Metformin as an anti-cancer agent against bladder cancer acts via PD-L1 downregulation in an orthotopic mouse model.
     BMC Cancer. 2025;25:1534.
     PubMed    
     Abstract available
     
     

225. KANAAN MR, Schmitz J, Braesen JH, Kuczyk MA, et al
     Comparison of molecular profiles (Nectin-4 and TROP-2) in upper tract urothelial carcinoma with a positive history of urinary bladder cancer vs. UTUC only in the era of ADCs.
     BMC Cancer. 2025;25:1525.
     PubMed    
     Abstract available
     
     

226. ABOULHODA BE, Omar AM, Elfarrash S, Alghamdi MA, et al
     Novel anticancer effect of substituted imidazole derivatives against urothelial carcinoma: integrating In vitro screening and molecular docking for target kinases.
     BMC Cancer. 2025;25:1524.
     PubMed    
     Abstract available
     
     

227. LI W, Shi Y, Pu L, Zhang J, et al
     Shared decision-making in urinary reconstruction among radical cystectomy patients: a thematic analysis of patient and provider perspectives in China.
     BMC Cancer. 2025;25:1590.
     PubMed    
     Abstract available
     
     

228. FANG C, Huang X, Dai J, He W, et al
     Retraction Note: The circular RNA circfarsa sponges microRNA-330-5p in tumor cells with bladder cancer phenotype.
     BMC Cancer. 2025;25:1613.
     PubMed    
     
     
     

229. PARK Y, Xu W, Yang T, Hill V, et al
     STAG2 regulates polycomb and differentiation in urothelial precursors and bladder cancer.
     PLoS One. 2025;20:e0333128.
     PubMed    
     Abstract available